Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial



Arabi, Yaseen M, Gordon, Anthony C, Derde, Lennie PG, Nichol, Alistair D, Murthy, Srinivas, Al Beidh, Farah, Annane, Djillali, Al Swaidan, Lolowa, Beane, Abi, Beasley, Richard
et al (show 58 more authors) (2021) Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. INTENSIVE CARE MEDICINE, 47 (8). 867 - 886.

[img] Text
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 REMAP-CAP randomized controlled trial.pdf - OA Published Version

Download (1MB) | Preview
Item Type: Article
Uncontrolled Keywords: Adaptive platform trial, Intensive care, Pneumonia, Pandemic, COVID-19, Lopinavir-ritonavir, Hydroxychloroquine
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Clinical Directorate
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 20 May 2022 10:05
Last Modified: 03 Sep 2022 11:40
DOI: 10.1007/s00134-021-06448-5
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3134978